RxDoctor Payments Data

Seth Anderson, DPM

Foot & Ankle Surgery · Saint Louis, MONPI 1770553109

Payments from drug & device makers

What this record shows

This record is dominated by other: $42,424 of the $45,101 with a category attached, or 94.1%. Convatec Inc. accounts for 94.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $42,687 and has fallen 99.6% since, to $173 in 2025. Among foot & ankle surgery clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,101in general payments, 2019–2025

Across 41 payments — averaging $1100.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$43K
  • Triad Life Sciences Inc.$2K
  • Stryker$330
  • Angiodynamics, Inc.$118
  • Medtronic$57
  • Smith+Nephew$43
  • plus $185 from 8 others

What the payments were for

  • Consulting fees$1,5003%
  • Food & beverage$1,1773%
  • Other$42,42494%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,101 in reported general payments places this provider in the 90th percentile of 163 foot & ankle surgery providers in Missouri.

See all foot & ankle surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$118,107
Medicare patients
422
Services billed
5,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole16$19,689
Gentamicin Sulfate23$808
Gabapentin56$579
Doxycycline Hyclate29$339
Terbinafine Hcl45$220
Methylprednisolone36$200
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen37$189
Ammonium Lactate11$179
Meloxicam69$142
Ketoconazole21$87
Tramadol Hcl14$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$31$19,68916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 163 foot & ankle surgery providers in Missouri.

Other foot & ankle surgery in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →